Market Cap 370.80M
Revenue (ttm) 40,000.00
Net Income (ttm) -88.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220,225.00%
Debt to Equity Ratio 0.15
Volume 2,286,900
Avg Vol 4,178,070
Day's Range N/A - N/A
Shares Out 130.11M
Stochastic %K 9%
Beta 0.18
Analysts Strong Sell
Price Target $16.61

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
Amnesiac
Amnesiac May. 17 at 11:11 AM
$ALT Just a Sunday morning thought… maybe they are about to release some additional findings at Best of EASL that will re-rate the company, hence the massive investment from big whales… We might get PR on Thursday May 28… It has however 80% chance of being a nothing burger!
1 · Reply
Corpkcots
Corpkcots May. 17 at 10:25 AM
0 · Reply
StockDark
StockDark May. 17 at 8:22 AM
$ALT Prime turn-key window for an acquirer to step in before the phase 3 officially starts moving in the second half of the year.
0 · Reply
Turribull
Turribull May. 17 at 7:00 AM
0 · Reply
artiebet
artiebet May. 16 at 10:41 PM
$ALT i know you all appreciate a gamble. We're invested here. Preakness Stakes maiden Ocelli for win! https://puntrs.io/punt/ce238a20-bde5-4607-ae97-fffd9644ec14
0 · Reply
blankstocker
blankstocker May. 16 at 7:13 PM
$ALT I wonder what this is about exactly - Shark Tank format? 
2 · Reply
BuddyBoy6975
BuddyBoy6975 May. 16 at 7:01 PM
$ALT Gotta ask GS…..
0 · Reply
Damnthisappilosthistory
Damnthisappilosthistory May. 16 at 6:10 PM
$ALT any proof to “89bio and Akero both took off after EASL”? Seems ridiculous to me looking at their stock price history and respective EASL dates.
2 · Reply
TDGREEN
TDGREEN May. 16 at 3:44 PM
$ALT anyone think this could be a catalyst to higher share price this month? “A late-breaking oral presentation on the 48-week IMPACT data in MASH will be delivered by Dr. Mazen Noureddin, Professor of Medicine, Houston Methodist Hospital; Chief Scientific Officer and Co-Chairman, Summit Clinical Research, on May 28, 2026 at 5 p.m. CEST. Abstract selected as “Best of EASL 2026”.”
5 · Reply
Hatrak1
Hatrak1 May. 16 at 3:12 PM
$ALT They are the initial yank on the shorts of the big wedgie in the sky ! 🤣
0 · Reply
Latest News on ALT
Altimmune price target lowered to $11 from $14 at Citizens

2026-05-14T09:47:49.000Z - 3 days ago

Altimmune price target lowered to $11 from $14 at Citizens


Altimmune Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 days ago

Altimmune Earnings Call Transcript: Q1 2026


Altimmune reports Q1 EPS (18c), consensus (25c)

2026-05-13T11:59:47.000Z - 4 days ago

Altimmune reports Q1 EPS (18c), consensus (25c)


Altimmune management to meet with Piper Sandler

2026-04-27T19:56:05.000Z - 19 days ago

Altimmune management to meet with Piper Sandler


Altimmune upgraded to Neutral from Sell at Goldman Sachs

2026-04-24T09:16:13.000Z - 23 days ago

Altimmune upgraded to Neutral from Sell at Goldman Sachs


Altimmune 64.25M share Spot Secondary priced at $3.00

2026-04-23T11:06:36.000Z - 24 days ago

Altimmune 64.25M share Spot Secondary priced at $3.00


Altimmune announces common stock offering, no amount given

2026-04-22T20:28:30.000Z - 24 days ago

Altimmune announces common stock offering, no amount given


Altimmune Transcript: AGM 2026

Apr 16, 2026, 8:30 AM EDT - 4 weeks ago

Altimmune Transcript: AGM 2026


Altimmune initiated with a Buy at Truist

2026-03-18T20:00:19.000Z - 2 months ago

Altimmune initiated with a Buy at Truist


Altimmune Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 9:20 AM EDT - 2 months ago

Altimmune Transcript: Leerink Global Healthcare Conference 2026


Altimmune Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 2:15 PM EDT - 2 months ago

Altimmune Transcript: The Citizens Life Sciences Conference 2026


Altimmune price target lowered to $13 from $18 at B. Riley

2026-03-06T13:40:07.000Z - 2 months ago

Altimmune price target lowered to $13 from $18 at B. Riley


Altimmune Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 2 months ago

Altimmune Earnings Call Transcript: Q4 2025


Altimmune reports Q4 EPS (27c), consensus (24c)

2026-03-05T12:14:56.000Z - 2 months ago

Altimmune reports Q4 EPS (27c), consensus (24c)


Altimmune to Participate in Upcoming Investor Conferences

Mar 2, 2026, 7:30 AM EST - 2 months ago

Altimmune to Participate in Upcoming Investor Conferences


Altimmune management to meet with Piper Sandler

2026-02-20T14:12:05.000Z - 3 months ago

Altimmune management to meet with Piper Sandler


Altimmune initiated with a Buy at Titan Partners

2026-02-13T14:55:31.000Z - 3 months ago

Altimmune initiated with a Buy at Titan Partners


Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

2026-01-28T08:09:07.000Z - 3 months ago

Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

LLY NVO


Altimmune prices $75M registered direct offering

2026-01-28T05:35:22.000Z - 3 months ago

Altimmune prices $75M registered direct offering


Altimmune initiated with an Overweight at Barclays

2026-01-27T21:27:07.000Z - 3 months ago

Altimmune initiated with an Overweight at Barclays


Altimmune initiated with an Overweight at Barclays

2026-01-27T21:16:41.000Z - 3 months ago

Altimmune initiated with an Overweight at Barclays


Altimmune Transcript: Study Result

Dec 19, 2025, 8:00 AM EST - 5 months ago

Altimmune Transcript: Study Result


Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 5 months ago

Altimmune Announces CEO Transition and Succession Plan


Altimmune Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 6 months ago

Altimmune Transcript: Stifel 2025 Healthcare Conference


Altimmune Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 6 months ago

Altimmune Earnings Call Transcript: Q3 2025


Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 6 months ago

Altimmune to Participate in Two Upcoming Investor Conferences


Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 10:30 AM EDT - 8 months ago

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum


Altimmune Transcript: AGM 2025

Sep 25, 2025, 8:30 AM EDT - 8 months ago

Altimmune Transcript: AGM 2025


Amnesiac
Amnesiac May. 17 at 11:11 AM
$ALT Just a Sunday morning thought… maybe they are about to release some additional findings at Best of EASL that will re-rate the company, hence the massive investment from big whales… We might get PR on Thursday May 28… It has however 80% chance of being a nothing burger!
1 · Reply
Corpkcots
Corpkcots May. 17 at 10:25 AM
0 · Reply
StockDark
StockDark May. 17 at 8:22 AM
$ALT Prime turn-key window for an acquirer to step in before the phase 3 officially starts moving in the second half of the year.
0 · Reply
Turribull
Turribull May. 17 at 7:00 AM
0 · Reply
artiebet
artiebet May. 16 at 10:41 PM
$ALT i know you all appreciate a gamble. We're invested here. Preakness Stakes maiden Ocelli for win! https://puntrs.io/punt/ce238a20-bde5-4607-ae97-fffd9644ec14
0 · Reply
blankstocker
blankstocker May. 16 at 7:13 PM
$ALT I wonder what this is about exactly - Shark Tank format? 
2 · Reply
BuddyBoy6975
BuddyBoy6975 May. 16 at 7:01 PM
$ALT Gotta ask GS…..
0 · Reply
Damnthisappilosthistory
Damnthisappilosthistory May. 16 at 6:10 PM
$ALT any proof to “89bio and Akero both took off after EASL”? Seems ridiculous to me looking at their stock price history and respective EASL dates.
2 · Reply
TDGREEN
TDGREEN May. 16 at 3:44 PM
$ALT anyone think this could be a catalyst to higher share price this month? “A late-breaking oral presentation on the 48-week IMPACT data in MASH will be delivered by Dr. Mazen Noureddin, Professor of Medicine, Houston Methodist Hospital; Chief Scientific Officer and Co-Chairman, Summit Clinical Research, on May 28, 2026 at 5 p.m. CEST. Abstract selected as “Best of EASL 2026”.”
5 · Reply
Hatrak1
Hatrak1 May. 16 at 3:12 PM
$ALT They are the initial yank on the shorts of the big wedgie in the sky ! 🤣
0 · Reply
golfeveryday
golfeveryday May. 16 at 3:10 PM
$ALT ‘Best of EASL’ means the liver community found the analysis scientifically interesting, potentially clinically important, and differentiated vs standard GLP-1 data. They may show standard pathology still says ‘F3’ but digital pathology shows collagen reduction, thinner fibrotic bands and reduced inflammation - this suggests fibrosis is improving biologically at 24 weeks before crossing the official one stage standard read biopsy threshold. Telling this story through digital pathology regains confidence that fibrosis regression is happening very quickly and is difficult to detect with standard human biopsy, which materially changes confidence in P3 late stage outcomes at 52 weeks evaluated by digital pathology. It’s essentially a forward view of what Phase 3 data could reveal and highlights how quick (24 weeks) Pemvidutide has an impact on fibrosis. Keep me honest @Wolly99 @FatMoneyScience @Cryptobearcat
2 · Reply
MineMineItsAllMine
MineMineItsAllMine May. 16 at 1:59 PM
$ALT I do not believe the 4 horsemen who recently participated in the "over-subscribed offering" will be releasing their shares into the market to make a quick buck. However, remember Alyeska Investment Group, L.P., they were the entity who acquired: - 12,397,920 Shares of Common Stock - Pre-Funded Warrants to Purchase 4,647,534 Shares of Common Stock - that equals 17,045,454 shares ...and then we find out they sold 9,913,201 shares, leaving them with: - Alyeska Master Fund, L.P.(2) 7,132,453 - (2) This information is based solely on information provided to us from Alyeska Master Fund, L.P. on March 2, 2026. ...On 2026-05-15 they filed a 13F, and they now have: - 2,644,600 shares Likely providing a possible source for the recent large increase in shares shorted...20 M to 35 M.
2 · Reply
Amnesiac
Amnesiac May. 16 at 1:46 PM
$ALT Best of EASL gives the 48-week data more scientific credibility. What could make it more impactful The stock reaction depends on whether EASL reveals new details beyond the prior PR/deck: * stronger fibrosis/NIT responder data * digital pathology showing fibrosis regression * better dose-response clarity * 2.4 mg rationale becoming more convincing * clean safety/tolerability details * commentary from Dr. Noureddin that strengthens confidence If it is just a polished repeat of known 48-week data, impact may be modest. Realistic stock effect * Repeat data only: small help, maybe sentiment support * New compelling fibrosis / pathology detail: meaningful upside * Strong KOL framing + clear Phase 3 confidence: could help stabilize and re-rate gradually Bottom line EASL probably helps the credibility floor more than it creates an immediate breakout. The bigger catalysts remain: AUD data, partnership, Phase 3 initiation, and any regulatory/PRIME update.
4 · Reply
Wolly99
Wolly99 May. 16 at 11:55 AM
$ALT good piece on MetALD. I think this could also be a focus for pemvi…and I might not spend the resources needed on a p3 in AUD or ALD if the MASH p3 is successful and pemvi can be prescribed for MetALD in addition to MASH https://www.statnews.com/2026/05/13/liver-disease-metald-examined-part-3-stat-series-deadliest-drug/
1 · Reply
artiebet
artiebet May. 16 at 11:42 AM
$ALT top of the table!
2 · Reply
Paul4321
Paul4321 May. 16 at 9:58 AM
$ALT Cars in the mirror are closer then they seem. ALT starts MASH second half 2026. Realistic estimate for interim/topline readout base case 2H 2028. The market typically starts materially re-rating a P3 MASH asset about 6-18 months before interim readout (thats based on other MASH cases Madrigal, Akero, Intercept). So re-rate sometime in 2027 or early 2028. And yes took into account large global trial. While ive not been happy I cant over look that the SP is way under priced, and risk is minimal compared to reward.
0 · Reply
StockDark
StockDark May. 16 at 8:16 AM
$ALT stop taking bullish options setup for June 18th seriously.
0 · Reply
JdNews
JdNews May. 16 at 6:46 AM
$ALT Here. My point exactly. You invested. Invested into Alt. Like you invested in Meta. Or Amazon. Or Nvidia. lol. That’s your mistake. Then yoh want to blame it on someone else. You are in a penny stock. In Pennie’s you sell the highs. Buy back with more shares. I should sell a workshop
1 · Reply
JdNews
JdNews May. 16 at 6:28 AM
$ALT I love thiz. Board is still buzzing at 2 am. On a Friday. Im buzzing as well. But, there is no short squeeze here. That was back when we had 70 million shares in 2020z. But. We could go up stair stepping. As I’ve always said. We have to watch L2. There is 100k still at 3.20z. If we go up either it gets eaten. Or it goes bye bye. Maybe next week they get tired.
1 · Reply
BuddyBoy6975
BuddyBoy6975 May. 16 at 6:18 AM
$ALT $CRDF $LABU Wrong board. Blocked
0 · Reply
JdNews
JdNews May. 16 at 5:29 AM
$ALT No not delusional at all. You’re just unhappy as I see you bought in the 4s.. That’s to be expected cuz you wrrr all hung ho a week ago and now you’re turning. Like a zombie turns in Walking Dead. It’s ok. We will go higher. Shorts have a stranglehold on 3.20 fir a minute
1 · Reply
JdNews
JdNews May. 16 at 5:07 AM
$ALT As I told many stories here. I sold yhst high on the side of 95 from Hollywood to Miami. Had to learn Spanish. Quick. Y tu tambien, Florida is going to the billionaires. There all moving there. Maybe Durso should be down in Palm Beach.
0 · Reply